Type 1 Diabetes Mellitus Clinical Trials in Atlanta, Georgia

5 studies are recruiting for type 1 diabetes mellitus in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Type 1 Diabetes Extension Study

   This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long…

   Stage

   Not phased

   Ages

   8 to 35

   Site

   Emory University, Atlanta, Georgia

   Locations

   12 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT02734277 on ClinicalTrials.gov

2. A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

   This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenou…

   Stage

   Phase 3

   Ages

   1 to 25

   Site

   Atlanta Diabetes Associates- Site Number : 8400036, Atlanta, Georgia

   Locations

   197 in total

   Run by

   Sanofi

   See if you can join NCT07088068 on ClinicalTrials.gov

3. CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

   This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evalua…

   Stage

   Phase 1

   Ages

   12 to 35

   Site

   Atlanta Diabetes Association, Atlanta, Georgia

   Locations

   45 in total

   Run by

   COUR Pharmaceutical Development Company, Inc.

   See if you can join NCT06783309 on ClinicalTrials.gov

4. Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

   This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.

   Stage

   Not phased

   Ages

   14 to 75

   Site

   Emory University, Atlanta, Georgia

   Locations

   11 in total

   Run by

   Insulet Corporation

   See if you can join NCT07579702 on ClinicalTrials.gov

5. Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM

   This is a prospective, single arm, open-label, interventional, pilot study to evaluate the accuracy and precision of the continuous glucose monitoring (CGM) system of i-SENS, Inc., CareSens Air 3, in adult patients with type 1 diabetes.

   Stage

   Not phased

   Ages

   18 to 65

   Site

   Atlanta Diabetes Associates, Atlanta, Georgia

   Locations

   4 in total

   Run by

   i-SENS, Inc.

   See if you can join NCT07296276 on ClinicalTrials.gov